Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Livial TM
Active ingredients: tibolone
What it is used for
Short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. Second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. After careful selection of users, Livial should be prescribed for the shortest duration consistent with treatment goals. Review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer Clinical Trials and Precautions). Livial should only be continued for as long as the benefit outweighs the risks.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Protect from Moisture
- Protect from Light
- Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
6mm diameter white, round, flat tablets with bevelled edge coded "MK" above "2" on one side and "Organon" and a star on the other.
Images are the copyright of Medicines Information Pty Ltd
We are currently experiencing issues with Medicines Information data. Images displayed may not be current, please refer to the CMI.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Over 65?
This medicine contains the active ingredients:
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pregnant or planning a pregnancy?
For the active ingredient tibolone
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Vaginal health after breast cancer: A guide for patients - Australasian Menopause Society
Women who have had breast cancer treatment before menopause might find they develop symptoms such as hot flushes, night sweats, joint aches and vaginal dryness. These are symptoms of low oestrogen, which occur naturally with age, but may also occur in younger women undergoing treatment for breast cancer. These changes are called the genito-urinary syndrome of menopause (GSM), which was previously known as atrophic vaginitis.
Read more on Australasian Menopause Society website
Top results
Tibolone as menopausal hormone therapy - Australasian Menopause Society
Tibolone is a synthetic steroid molecule which is, in essence, a progestogen. Post absorption, its metabolites have oestrogenic, progestogenic and androgenic properties
Read more on Australasian Menopause Society website
AMS Guide to Equivalent MHT/HRT Doses Australia only - Australasian Menopause Society
Information Sheet has been developed as a guideline only to approximately equivalent doses of the different MHT/HRT products available in Australia.
Read more on Australasian Menopause Society website
Osteoporosis - Australasian Menopause Society
Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during a woman’s 20s to 30s when the skeleton has stopped growing and bones are at their strongest. The female sex hormone oestrogen plays an important role in maintaining bone strength. After menopause oestrogen levels drop and this may result in increased bone loss. The average woman loses up to 10 per cent of
Read more on Australasian Menopause Society website